News related to Risperdal Consta (Risperidone) and/or conditions it is approved for
Janssen Pharmaceuticals, Inc. to plead guilty and pay over $1.6 billion to resolve allegations of misbranding and filing false claims for Risperdal
Source: Litigation / Medical Malpractice News From Medical News Today [2013.11.06]
On behalf of the U.S. Food and Drug Administration, the U.S. Department of Justice on November 4th, 2013 announced a guilty plea agreement with Janssen Pharmaceuticals, Inc., (JPI) of Titusville, N.J., and a $400 million criminal fine for introducing a misbranded drug, Risperdal (risperidone), into interstate commerce. A Johnson & Johnson Company, JPI must also pay $1.